OncoMatch/Clinical Trials/NCT06056752
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Is NCT06056752 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including QH103 Cell and Fludarabine for b-cell acute lymphoblastic leukemia.
Treatment: QH103 Cell · Fludarabine · Cyclophosphamide — This is a single-arm, single-center, interventional, dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: immune cell therapy
Cannot have received: donor lymphocyte infusion
Lab requirements
Kidney function
serum creatinine≤1.5 × upper limit of normal range (uln)
Liver function
glutamine aminotransferase, aspartate aminotransferase ≤3 times uln, total bilirubin ≤1.5 times uln
Cardiac function
left ventricular ejection fraction ≥50% on echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06056752 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune cell therapy, donor lymphocyte infusion disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages